Palvella Therapeutics, Inc. Current Liabilities
Palvella Therapeutics, Inc. (PVLA) had Current Liabilities of $11.95 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-04
- 2026-06-30: Liabilities, Current $11.95M.
- 2026-03-31: Liabilities, Current $9.12M.
- 2025-12-31: Liabilities, Current $11.34M.
- 2025-09-30: Liabilities, Current $10.31M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $11.95M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $9.12M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $11.34M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $10.31M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $9.62M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $8.98M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $12.04M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $4.25M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $6.35M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $7.53M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $2.36M 10-K · filed 2025-03-31 | $11.92M 10-K · filed 2024-03-29 |
| 2023-09-30 | $28.87M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $34.37M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $42.88M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $36.58M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $33.52M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $35.55M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $39.48M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $50.56M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $49.70M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $43.93M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $30.27M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $22.14M 10-K · filed 2022-03-02 | |
| 2020-09-30 | $19.69M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $18.26M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $20.48M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $27.00M 10-K · filed 2021-03-31 | |
| 2019-09-30 | $39.85M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $40.93M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $41.13M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $48.08M 10-K · filed 2020-03-13 | |
| 2018-09-30 | $40.59M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $52.33M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $54.76M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $45.77M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $39.04M 10-Q · filed 2017-11-13 | |
| 2017-06-30 | $35.80M 10-Q · filed 2017-08-11 | |
| 2017-03-31 | $11.44M 10-Q · filed 2017-05-15 | |
| 2016-12-31 | $8.38M 10-K · filed 2018-03-15 | $8.38M 10-K · filed 2017-03-30 |
| 2016-09-30 | $9.95M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $6.42M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $6.50M 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $2.80M 10-K · filed 2017-03-30 | |
| 2015-09-30 | $2.24M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $3.02M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $2.25M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $3.52M 10-K · filed 2016-03-23 | $3.54M 10-K · filed 2015-03-30 |
| 2014-06-30 | $1.12K 10-Q · filed 2014-12-12 | |
| 2013-12-31 | $1.77M 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |